Taiwan FDA clears GenomeFrontier’s IND application for GF-CART01, a CD20/CD19 dual targeting CAR T cell therapy for hematological B cell malignancies!

GenomeFrontier achieved a major milestone in its mission to develop innovative gene therapies and cell therapies that are affordable and therapeutically effective. On February 6, 2025, the Taiwan Food and Drug Administration (TFDA) cleared its Investigational New Drug (IND) application for GF-CART01, a CD20/CD19-directed dual targeting CAR T cell therapy for hematological B cell malignancies. GF-CART01 will be evaluated in a Phase 1 clinical trial to be conducted in Taiwan.